| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―Jun―30 |
Correction to “Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing” |
|
| 2 |
[GO] |
2025―May―19 |
Trust, Transparency, and Translation: How Clinical Pharmacologists Can Strengthen Public Confidence in Pandemic Responses-Commentary on Schmith et al. |
Brian W. Corrigan |
| 3 |
[GO] |
2024―Nov―13 |
The Impact of Dexamethasone and Prednisone on Apixaban and Rivaroxaban Exposure in COVID-19 Patients: A Physiologically Based Pharmacokinetic Modeling Study |
Jean Terrier, Kenza Abouir, Frederic Gaspar, Youssef Daali, Caroline Flora Samer |
| 4 |
[GO] |
2024―Oct―08 |
Selected Acute Safety Events Following the Use of Nirmatrelvir/Ritonavir or Molnupiravir for COVID-19: A Nationwide Cohort Study in South Korea |
Ju Hwan Kim, Ahhyung Choi, Gihwan Bae, Eun-Jeong Joo, Min Joo Choi, Kyungmin Huh, Hyungmin Lee, Jungyeon Kim, Dong-Hwi Kim, Min-Gyu Yoo, Il Uk Jo, Poong Hoon Lee, Geun Woo Lee, Hee Sun Jung, Jaehun Jung, Ju-Young Shin |
| 5 |
[GO] |
2024―Apr―27 |
Viral Kinetics Model of SARS-CoV-2 Infection Informs Drug Discovery, Clinical Dose, and Regimen Selection |
Allison M. Claas, Meelim Lee, Pai-Hsi Huang, Charles G. Knutson, Domenico Bullara, Birgit Schoeberl, Suzanne Gaudet |
| 6 |
[GO] |
2024―Mar―27 |
Impact of COVID-19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective |
Mohamed-Eslam F. Mohamed, Sandhya Girish, Rita Humeniuk, Silpa Nuthalapati, Amit Desai, Amita Datta-Mannan, Ferdous Gheyas, Jitendra Kanodia, Sravanthi Cheeti, Tong Zhu |
| 7 |
[GO] |
2024―Mar―05 |
How Much More Efficient Are Adaptive Platform Trials Than Multiple Stand-Alone Trials? A Comprehensive Simulation Study for Streamlining Drug Development During a Pandemic |
Masanao Sasaki, Hiroyuki Sato, Yukari Uemura, Ayako Mikami, Nao Ichihara, Shigeki Fujitani, Masashi Kondo, Yohei Doi, Eriko Morino, Daisuke Tokita, Norio Ohmagari, Wataru Sugiura, Akihiro Hirakawa |
| 8 |
[GO] |
2024―Mar―02 |
Physiologically Based Pharmacokinetic Modeling to Investigate the Disease-Drug-Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID-19 Patients with CYP2C19 Phenotypes |
Peile Wang, Shuaibing Liu, Jing Yang |
| 9 |
[GO] |
2024―Feb―13 |
Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID-19 Under the Emergency Use Authorization |
Qi Liu, Raj Nair, Ruihao Huang, Hao Zhu, Austin Anderson, Ozlem Belen, Van Tran, Rebecca Chiu, Karen Higgins, Jianmeng Chen, Lei He, Suresh Doddapaneni, Shiew-Mei Huang, Nikolay P. Nikolov, Issam Zineh |
| 10 |
[GO] |
2023―Oct―05 |
Neutralizing antibody levels as a correlate of protection against SARS-CoV-2 infection: a modeling analysis |
Guillaume Lingas, Delphine Planas, Hélène Péré, Françoise Porrot, Florence Guivel-Benhassine, Isabelle Staropoli, Darragh Duffy, Nicolas Chapuis, Camille Gobeaux, David Veyer, Constance Delaugerre, Jérôme Le Goff, Prunelle Getten, Jérôme Hadjadj, Adèle Bellino, Béatrice Parfait, Jean-Marc Treluyer, Olivier Schwartz, Jérémie Guedj, Solen Kernéis, Benjamin Terrier |
| 11 |
[GO] |
2023―Aug―12 |
Real-world evidence to supplement randomized clinical trials: Tocilizumab for severe COVID-19 pneumonia versus a cohort receiving standard of care |
Jacek Skarbinski, Heidi Fischer, Vennis Hong, Liyan Liu, Vincent M. Yau, Devin Incerti, Lei Qian, Bradley K. Ackerson, Laura B. Amsden, Sally F. Shaw, Sara Y. Tartof |
| 12 |
[GO] |
2023―Jun―22 |
Prognostic factors of COVID-19: an umbrella review endorsed by the International Society for Pharmacoepidemiology |
Grammati Sarri, Wei Liu, Luke Zabotka, Andreas Freitag, Ravinder Claire, Grace Wangge, Jamie Elvidge, Dalia Dawoud, Dimitri Bennett, Xuerong Wen, Xiaojuan Li, Christopher T. Rentsch, Md Jamal Uddin, M Sanni Ali, Mugdha Gokhale, Anouk Déruaz-Luyet, Daniela C. Moga, Jeff Jianfei Guo, Andrew R. Zullo, Elisabetta Patorno, Kueiyu Joshua Lin |
| 13 |
[GO] |
2023―Mar―25 |
Successes and Opportunities during the Pandemic: Reflections and Revelations from a Vaccine Development Perspective |
Penny M. Heaton, Kavitha Palaniappan, Anne-Claire Stona, Silke Vogel, John C. W. Lim |
| 14 |
[GO] |
2023―Feb―15 |
Mycophenolic acid exposure determines antibody formation following
SARS-CoV
-2 vaccination in kidney transplant recipients: a nested cohort study |
Soufian Meziyerh, Pim Bouwmans, Teun van Gelder, Danny van der Helm, Lianne Messchendorp, Paul J. M. van der Boog, Johan W. de Fijter, Dirk Jan A.R. Moes, Aiko P.J. de Vries |
| 15 |
[GO] |
2022―Nov―20 |
How a Pandemic Simultaneously Strengthened Existing Fundamentals and Drove New Innovations in Clinical Pharmacology |
Shirley K. Seo, Piet H. van der Graaf |
| 16 |
[GO] |
2022―Sep―09 |
CYP450 3A4
/5 Containment During
SARS-CoV
-2 Infection |
Jean Terrier, Camille Lenoir, Caroline Samer |
| 17 |
[GO] |
2022―Sep―06 |
Response to “
CYP450 3A4
/5 Containment During
SARS-CoV
-2 Infection” |
Edouard Charles Le Carpentier, Emmanuel Canet, Damien Masson, Ronan Bellouard, Matthieu Grégoire |
| 18 |
[GO] |
2022―Aug―19 |
Assessing the Combined Public Health Impact of Pharmaceutical Interventions on Pandemic Transmission and Mortality: An Example in
SARS CoV
-2 |
Mohamed A. Kamal, Andreas Kuznik, Luyuan Qi, Witold Więcek, Mohamed Hussein, Hazem E. Hassan, Kashyap Patel, Thomas Obadia, Masood Khaksar Toroghi, Daniela J. Conrado, Nidal Al-Huniti, Roman Casciano, Meagan P. O’Brien, Ruanne V. Barnabas, Myron S. Cohen, Patrick F. Smith |
| 19 |
[GO] |
2022―Jul―07 |
Comparative pharmacokinetics of tixagevimab/cilgavimab (
AZD7442
) administered intravenously versus intramuscularly in symptomatic
SARS-CoV
-2 infection |
Rachel A. Bender Ignacio, David A. Wohl, Rosalin Arends, Venkatesh Pilla Reddy, Ying Mu, Arzhang Cyrus Javan, Michael D. Hughes, Joseph J. Eron, Judith S. Currier, Davey Smith, Kara W. Chew, Michael Gibbs, Courtney V. Fletcher |
| 20 |
[GO] |
2022―May―14 |
Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir/ritonavir (Paxlovid
®
) and comedications |
Catia Marzolini, Daniel R. Kuritzkes, Fiona Marra, Alison Boyle, Sara Gibbons, Charles Flexner, Anton Pozniak, Marta Boffito, Laura Waters, David Burger, David J. Back, Saye Khoo |
| 21 |
[GO] |
2022―May―05 |
Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration |
Shiri Guy-Alfandary, Sasha Zhurat, Maya Berlin, Tal De Haan, Itai Gueta, Renata Shihmanter, Ahuva Golik, Matitiahu Berkovitch, Sara Eyal, Lee H. Goldstein |
| 22 |
[GO] |
2022―Apr―07 |
Innovative Randomized Phase 1 Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir |
Ravi Shankar P. Singh, Sima S. Toussi, Frances Hackman, Phylinda L. Chan, Rohit Rao, Richard Allen, Lien Van Eyck, Sylvester Pawlak, Eugene P. Kadar, Frances Clark, Haihong Shi, Annaliesa S. Anderson, Michael Binks, Sandeep Menon, Gianluca Nucci, Arthur Bergman |
| 23 |
[GO] |
2022―Apr―05 |
Physiologically Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID-19 in Geriatrics |
Ziteng Wang, Eric Chun Yong Chan |
| 24 |
[GO] |
2022―Mar―16 |
PBPK-led guidance for cystic fibrosis patients taking elexacaftor-tezacaftor-ivacaftor with nirmatrelvir-ritonavir for the treatment of COVID-19 |
Eunjin Hong, Lisa M. Almond, P.S. Chung, A. Peter Rao, Paul M. Beringer |
| 25 |
[GO] |
2022―Feb―16 |
ISPE-Endorsed Guidance in Using Electronic Health Records for Comparative Effectiveness Research in COVID-19: Opportunities and Trade-Offs |
Grammati Sarri, Dimitri Bennett, Thomas Debray, Anouk Deruaz-Luyet, Montse Soriano Gabarró, Joan A. Largent, Xiaojuan Li, Wei Liu, Jennifer L. Lund, Daniela C. Moga, Mugdha Gokhale, Christopher T. Rentsch, Xuerong Wen, Chen Yanover, Yizhou Ye, Huifeng Yun, Andrew R. Zullo, Kueiyu Joshua Lin |
| 26 |
[GO] |
2022―Feb―10 |
Identification of risk factors for COVID-19 hospitalisation in patients with anti-rheumatic drugs: results from a multicentre nested case control study’ |
Merel A.A. Opdam, Sophie Benoy, Lise M. Verhoef, Sandra Van Bijnen, Femke Lamers-Karnebeek, R.A.M. Traksel, Petra Vos, Alfons A. den Broeder, Jasper Broen |
| 27 |
[GO] |
2022―Feb―08 |
The Pandemic as a Catalyst for Disruptive Innovation in Clinical Pharmacology |
Kathleen M. Giacomini, Piet H. Graaf |
| 28 |
[GO] |
2022―Jan―28 |
The impact of Covid-19 on the initiation of clinical trials in Europe and the United States |
Florian Lasch, Eftychia-Eirini Psarelli, Ralf Herold, Andrea Mattsson, Lorenzo Guizzaro, Frank Pétavy, Anja Schiel |
| 29 |
[GO] |
2021―Dec―10 |
Exogenous sex hormones and sex hormone receptor modulators in COVID-19 ― rationale and clinical pharmacology considerations |
Peng Zou, Agiua Heath, Catherine Sewell, Yanhui Lu, Doanh Tran, Shirley K. Seo |
| 30 |
[GO] |
2021―Dec―04 |
Anticoagulant treatment regimens in patients with Covid-19: a meta-analysis |
Anselm Jorda, Jolanta M. Siller-Matula, Markus Zeitlinger, Bernd Jilma, Georg Gelbenegger |
| 31 |
[GO] |
2021―Dec―03 |
Features of inflammatory heart reactions following mRNA COVID-19 vaccination at a global level |
Laurent Chouchana, Alice Blet, Mohammad Al-Khalaf, Tahir S. Kafil, Girish Nair, James Robblee, Milou-Daniel Drici, Marie-Blanche Valnet-Rabier, Joëlle Micallef, Francesco Salvo, Jean-Marc Treluyer, Peter P. Liu |
| 32 |
[GO] |
2021―Nov―22 |
Model Informed Drug Development Approaches to Assist New Drug Development in the COVID-19 Pandemic |
Ye Xiong, Jianghong Fan, Eliford Kitabi, Xinyuan Zhang, Youwei Bi, Manuela Grimstein, Yuching Yang, Justin C Earp, Nan Zheng, Jiang Liu, Yaning Wang, Hao Zhu |
| 33 |
[GO] |
2021―Nov―11 |
Science, Innovation, and Society in the Age of Pandemics: Reflections from the Inaugural Sir Alasdair Breckenridge Lecture |
Nokuthula Sikhethiwe Kitikiti, Uttara Soumyanarayanan, Silke Vogel, John C. W. Lim |
| 34 |
[GO] |
2021―Oct―26 |
An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2 |
Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, Rebecca Lyon, Michael Fisher, Karen Martin, Izabela Eberhart, Christie Woods, Sean Ewings, Colin Hale, Rajith KR Rajoli, Laura Else, Sujan Dilly-Penchala, Alieu Amara, David G Lalloo, Michael Jacobs, Henry Pertinez, Parys Hatchard, Robert Waugh, Megan Lawrence, Lucy Johnson, Keira Fines, Helen Reynolds, Timothy Rowland, Rebecca Crook, Emmanuel Okenyi, Kelly Byrne, Pavel Mozgunov, Thomas Jaki, Saye Khoo, Andrew Owen, Gareth Griffiths, Thomas E Fletcher |
| 35 |
[GO] |
2021―Sep―18 |
Scholarly Productivity in Clinical Pharmacology Amid Pandemic-Related Workforce Disruptions: Are Men and Women Affected Equally? |
Alethea B. Gerding, Sharon J. Swan, Kimberly A. Brayer, Susan M. Abdel-Rahman |
| 36 |
[GO] |
2021―Sep―13 |
Population pharmacokinetics and pharmacodynamics of the neutralizing antibodies bamlanivimab and etesevimab in patients with mild to moderate COVID-19 infection |
Emmanuel Chigutsa, Lisa O’Brien, Lisa Ferguson-Sells, Amanda Long, Jenny Chien |
| 37 |
[GO] |
2021―Sep―08 |
Physiologically based pharmacokinetic modelling to investigate the impact of the cytokine storm on CYP3A drug pharmacokinetics in COVID-19 patients |
Felix Stader, Manuel Battegay, Parham Sendi, Catia Marzolini |
| 38 |
[GO] |
2021―Sep―02 |
Impact of SARS-CoV-2 infection (COVID-19) on cytochromes P450 activity assessed by the Geneva cocktail |
Camille Lenoir, Jean Terrier, Yvonne Gloor, François Curtin, Victoria Rollason, Jules Alexandre Desmeules, Youssef Daali, Jean-Luc Reny, Caroline Flora Samer |
| 39 |
[GO] |
2021―Aug―29 |
First in Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients with COVID-19 |
Peter Chen, Gourab Datta, Ying Grace Li, Jenny Chien, Karen Price, Emmanuel Chigutsa, Patricia Brown-Augsburger, Josh Poorbaugh, Jeffrey Fill, Robert J. Benschop, Nadine Rouphael, Ariel Kay, Mark J. Mulligan, Amit Saxena, William A. Fischer, Michael Dougan, Paul Klekotka, Ajay Nirula, Charles Benson |
| 40 |
[GO] |
2021―Jul―27 |
DrugWAS: Drug-wide association studies for COVID-19 drug repurposing |
Cosmin A. Bejan, Katherine N. Cahill, Patrick J. Staso, Leena Choi, Josh F. Peterson, Elizabeth J. Phillips |
| 41 |
[GO] |
2021―Jul―09 |
US Taxpayers Heavily Funded the Discovery of COVID-19 Vaccines |
Hussain S. Lalani, Jerry Avorn, Aaron S. Kesselheim |
| 42 |
[GO] |
2021―Jun―17 |
Heterogeneity in COVID-19 Convalescent Plasma Clinical Trials |
Mirco Müller-Olling, Ute Vahlensieck, Anneliese Hilger |
| 43 |
[GO] |
2021―Jun―04 |
Association between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: an observational multicenter study |
Nicolas Hoertel, Marina Sánchez-Rico, Erich Gulbins, Johannes Kornhuber, Alexander Carpinteiro, Eric J. Lenze, Angela M. Reiersen, Miriam Abellán, Pedro De La Muela, Raphaël Vernet, Carlos Blanco, Céline Cougoule, Nathanaël Beeker, Antoine Neuraz, Philip Gorwood, Jesús M. Alvarado, Pierre Meneton, Frédéric Limosin, Pierre-Yves Ancel, Alain Bauchet, Nathanaël Beeker, Vincent Benoit, Mélodie Bernaux, Ali Bellamine, Romain Bey, Aurélie Bourmaud, Stéphane Breant, Anita Burgun, Fabrice Carrat, Charlotte Caucheteux, Julien Champ, Sylvie Cormont, Christel Daniel, Julien Dubiel, Catherine Ducloas, Loic Esteve, Marie Frank, Nicolas Garcelon, Alexandre Gramfort, Nicolas Griffon, Olivier Grisel, Martin Guilbaud, Claire Hassen-Khodja, François Hemery, Martin Hilka, Anne Sophie Jannot, Jerome Lambert, Richard Layese, Judith Leblanc, Léo Lebouter, Guillaume Lemaitre, Damien Leprovost, Ivan Lerner, Kankoe Levi Sallah, Aurélien Maire, Marie-France Mamzer, Patricia Martel, Arthur Mensch, Thomas Moreau, Antoine Neuraz, Nina Orlova, Nicolas Paris, Bastien Rance, Hélène Ravera, Antoine Rozes, Elisa Salamanca, Arnaud Sandrin, Patricia Serre, Xavier Tannier, Jean-Marc Treluyer, Damien Van Gysel, Gaël Varoquaux, Jill Jen Vie, Maxime Wack, Perceval Wajsburt, Demian Wassermann, Eric Zapletal |
| 44 |
[GO] |
2021―May―25 |
Japan’s special approval for emergency system during COVID-19 pandemic |
Hideki Maeda |
| 45 |
[GO] |
2021―Apr―22 |
Japan’s Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir |
Munetaka Ueda, Tetsuya Tanimoto, Anju Murayama, Akihiko Ozaki, Masahiro Kami |
| 46 |
[GO] |
2021―Apr―01 |
Effect of corticosteroids on mortality in hospitalized COVID-19 patients not receiving invasive mechanical ventilation |
Federica Fusina, Filippo Albani, Enza Granato, Angelo Meloni, Renzo Rozzini, Tony Sabatini, Roberto Stellini, Paolo Terragnoli, Antonio Rosano, Mohammed Abu Hilal, Giuseppe Natalini |
| 47 |
[GO] |
2021―Mar―14 |
Clinical Pharmacology-Informed Development of COVID-19 Therapeutics: Regulatory Experience |
Su-Young Choi, Vikram Arya, Kellie Reynolds |
| 48 |
[GO] |
2021―Mar―05 |
COVID-19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European Union |
Amos Jochanan de Jong, Yared Santa-Ana-Tellez, Ghislaine José Madeleine Wilhelmien van Thiel, Mira Gerta Petra Zuidgeest, Satu Johanna Siiskonen, Dinesh Mistry, Anthonius de Boer, Helga Gardarsdottir |
| 49 |
[GO] |
2021―Feb―28 |
Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies |
Silke Gastine, Juanita Pang, Florencia A.T. Boshier, Simon J. Carter, Dagan O. Lonsdale, Mario Cortina-Borja, Ivan F.N. Hung, Judy Breuer, Frank Kloprogge, Joseph F. Standing |
| 50 |
[GO] |
2021―Feb―08 |
Neglecting plasma protein binding in COVID-19 patients leads to a wrong interpretation of lopinavir overexposure |
Francoise Stanke-Labesque, Didier Concordet, Zoubir Djerada, Stéphane Bouchet, Caroline Solas, Etienne Mériglier, Fabrice Bonnet, Bruno Mourvillier, Stéphanie Ruiz, Guillaume Martin-Blondel, Olivier Epaulard, Carole Schwebel, Elodie Gautier-Veyret, Peggy Gandia |
| 51 |
[GO] |
2021―Feb―05 |
Real-world evidence for assessing pharmaceutical treatments in the context of COVID-19 |
Jessica M. Franklin, Kueiyu Joshua Lin, Nicolle Gatto, Jeremy Rassen, Robert J. Glynn, Sebastian Schneeweiss |
| 52 |
[GO] |
2021―Jan―28 |
RAAS blockade and COVID-19: Mechanistic Modeling of mas and AT1 Receptor Occupancy as Indicators of Pro- and Anti-Inflammatory Balance |
Karen Melissa Hallow, Ishaan Dave |
| 53 |
[GO] |
2021―Jan―28 |
Collaborative platform trials to fight COVID-19: methodological and regulatory considerations for a better societal outcome |
Olivier Collignon, Carl-Fredrik Burman, Martin Posch, Anja Schiel |
| 54 |
[GO] |
2021―Jan―27 |
Physiologically-Based Pharmacokinetic Modeling of Remdesivir and its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients with COVID-19 |
Justin D. Lutz, Anita Mathias, Polina German, Cheryl Pikora, Sunila Reddy, Brian J. Kirby |
| 55 |
[GO] |
2021―Jan―10 |
Nonspecific binding considerations in the rational design and development of small molecule COVID-19 therapeutics |
Tristan S. Maurer |
| 56 |
[GO] |
2021―Jan―10 |
Mechanistic modelling of SARS-CoV-2 and other infectious diseases and the effects of therapeutics |
Alan S. Perelson, Ruian Ke |
| 57 |
[GO] |
2020―Dec―17 |
Increasing Use of Compassionate Use/Managed Access Channels to Obtain Medicines for Use in COVID-19 |
Paul Aliu, Séverine Sarp, Paige Fitzsimmons |
| 58 |
[GO] |
2020―Nov―19 |
COVIDOSE: A phase 2 clinical trial of low-dose tocilizumab in the treatment of non-critical COVID-19 pneumonia |
Garth W. Strohbehn, Brian L. Heiss, Sherin J. Rouhani, Jonathan A. Trujillo, Jovian Yu, Alec J. Kacew, Emily F. Higgs, Jeffrey C. Bloodworth, Alexandra Cabanov, Rachel C. Wright, Adriana K. Koziol, Alexandra Weiss, Keith Danahey, Theodore G. Karrison, Cuoghi C. Edens, Iazsmin Bauer Ventura, Natasha N. Pettit, Bhakti K. Patel, Jennifer Pisano, Mary E. Strek, Thomas F. Gajewski, Mark J. Ratain, Pankti D. Reid |
| 59 |
[GO] |
2020―Oct―28 |
Towards consensus on correct interpretation of protein binding in plasma and other biological matrices for COVID-19 therapeutic development |
Marta Boffito, David J Back, Charles Flexner, Peter Sjö, Terrence F. Blaschke, Peter W. Horby, Dario Cattaneo, Edward P Acosta, Peter Anderson, Andrew Owen |
| 60 |
[GO] |
2020―Sep―29 |
COVID-19: A Catalyst to Accelerate Global Regulatory Transformation |
Jerry Stewart, Peter Honig, Lina AlJuburi, Deborah Autor, Susan Berger, Patrick Brady, Helen Fitton, Carlos Garner, Michael Garvin, Mathias Hukkelhoven, Robert Kowalski, Sandra Milligan, Liza O’Dowd, Edward Reilly, Khyati Roberts, Andrew S. Robertson, Mark Taisey, Roopal Thakkar, Karin Van Baelen, Max Wegner |
| 61 |
[GO] |
2020―Sep―26 |
PharmGKB tutorial for pharmacogenomics of drugs potentially used in the context of COVID-19 |
Rachel Huddart, Michelle Whirl-Carrillo, Russ B. Altman, Teri E. Klein |
| 62 |
[GO] |
2020―Sep―21 |
Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study |
Huadong Yan, Ana M Valdes, Amrita Vijay, Shanbo Wang, Lili Liang, Shiqing Yang, Hongxia Wang, Xiaoyan Tan, Jingyuan Du, Susu Jin, Kecheng Huang, Fanrong Jiang, Shun Zhang, Nanhong Zheng, Yaoren Hu, Ting Cai, Guruprasad P. Aithal |
| 63 |
[GO] |
2020―Aug―27 |
Possible role of ABCB1 in lysosomal accumulation of azithromycin in COVID-19 therapy |
Jean-Michel Scherrmann |
| 64 |
[GO] |
2020―Aug―08 |
Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2 |
Aarzoo Thakur, Shawn Pei Feng Tan, James Chun Yip Chan |
| 65 |
[GO] |
2020―Jul―20 |
Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection |
Melanie R. Nicol, Abhay Joshi, Matthew L. Rizk, Philip E. Sabato, Radojka M. Savic, David Wesche, Jenny H. Zheng, Jack Cook |
| 66 |
[GO] |
2020―Jun―26 |
QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection |
Sok-Sithikun Bun, Philippe Taghji, Johan Courjon, Fabien Squara, Didier Scarlatti, Guillaume Theodore, Delphine Baudouy, Benjamin Sartre, Mohamed Labbaoui, Jean Dellamonica, Denis Doyen, Charles-Hugo Marquette, Jacques Levraut, Vincent Esnault, Sok-Siya Bun, Emile Ferrari |
| 67 |
[GO] |
2020―Jun―04 |
Pandemic Best Regulatory Practices: An Urgent Need in the Covid-19 Pandemic |
Murray M Lumpkin, John CW Lim |
| 68 |
[GO] |
2020―Jun―03 |
Applied Clinical Pharmacology in a Crisis - Interleukin-6 Axis Blockade and COVID-19 |
Garth W. Strohbehn, Pankti D. Reid, Mark J. Ratain |
| 69 |
[GO] |
2020―Jun―02 |
Oncology Treatment in the Era of COVID-19: We Cannot Afford to Hit the Pause Button |
Sarah A. Holstein, Julie M. Vose |
| 70 |
[GO] |
2020―May―23 |
A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19 |
Richard W Peck, Daniel Weiner, Jack Cook, J Robert Powell |
| 71 |
[GO] |
2020―May―21 |
Management of osteoarthritis during COVID-19 pandemic |
Enrico Ragni, Laura Mangiavini, Marco Viganò, Anna Teresa Brini, Giuseppe Michele Peretti, Giuseppe Banfi, Laura de Girolamo |
| 72 |
[GO] |
2020―May―14 |
Clinical trials for Covid-19: can we better use the short window of opportunity? |
Hans-Georg Eichler, Marco Cavaleri, Harald Enzmann, Francesca Scotti, Bruno Sepodes, Fergus Sweeney, Spiros Vamvakas, Guido Rasi |
| 73 |
[GO] |
2020―May―07 |
The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19 |
Virginia D. Schmith, Jie (Jessie) Zhou, Lauren RL Lohmer |
| 74 |
[GO] |
2020―May―01 |
Challenges in Drug Development Posed by the COVID-19 Pandemic: An Opportunity for Clinical Pharmacology |
Karthik Venkatakrishnan, Oezkan Yalkinoglu, Jennifer Q. Dong, Lisa J. Benincosa |
| 75 |
[GO] |
2020―Apr―30 |
COVID-19: a defining moment for clinical pharmacology? |
Piet H. van, Kathleen M. Giacomini |
| 76 |
[GO] |
2020―Apr―30 |
Dose rationale for favipiravir use in patients infected with SARS-CoV-2 |
Philippine Eloy, Caroline Solas, Franck Touret, France Mentré, Denis Malvy, Xavier de Lamballerie, Jérémie Guedj |
| 77 |
[GO] |
2020―Apr―30 |
Response to "Dose rationale for favipiravir use in patients infected with SARS-CoV-2" |
Yin-Xiao Du, Xiao-Ping Chen |
| 78 |
[GO] |
2020―Apr―29 |
Quantitative clinical pharmacology input to SARS-CoV-2 therapeutics should be based on robust data |
Joseph Standing |
| 79 |
[GO] |
2020―Apr―29 |
Response to “Quantitative clinical pharmacology input to SARS-CoV-2 therapeutics should be based on robust data” |
Maria Garcia-Cremades, Belen P. Solans, Emma Hughes, Jacqueline P. Ernest, Erika Wallender, Radojka M Savic |
| 80 |
[GO] |
2020―Apr―28 |
Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness |
Mahmoud Al-Kofahi, Pamala Jacobson, David R Boulware, Arthur Matas, Raja Kandaswamy, Mutaz M Jaber, Radha Rajasingham, Jo-Anne H Young, Melanie R Nicol |
| 81 |
[GO] |
2020―Apr―23 |
Incidence of Adverse Drug Reactions in COVID-19 patients in China: an active monitoring study by Hospital Pharmacovigilance System |
Ji Sun, Xuanyu Deng, Xiaoping Chen, Juanjuan Huang, Siqiong Huang, Yanfei Li, Jinhui Feng, Jiyang Liu, Gefei He |
| 82 |
[GO] |
2020―Apr―22 |
Chloroquine dosing recommendations for pediatric COVID-19 supported by modeling and simulation |
Laurens F.M. Verscheijden, Tjitske M. van der Zanden, Lianne P.M. van Bussel, Marika de Hoop-Sommen, Frans G.M. Russel, Trevor N. Johnson, Saskia N. de Wildt |
| 83 |
[GO] |
2020―Apr―22 |
Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence |
Krishna Sriram, Paul A. Insel |
| 84 |
[GO] |
2020―Apr―20 |
Off-Label Therapies for COVID-19-Are We All In This Together? |
Jonathan D. Alpern, Elie Gertner |
| 85 |
[GO] |
2020―Apr―17 |
Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19 |
Bharat Damle, Manoli Vourvahis, Erjian Wang, Joanne Leaney, Brian Corrigan |
| 86 |
[GO] |
2020―Apr―14 |
Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing |
Maria Garcia-Cremades, Belen P. Solans, Emma Hughes, Jacqueline P. Ernest, Erika Wallender, Francesca Aweeka, Annie Luetkemeyer, Radojka M Savic |
| 87 |
[GO] |
2020―Apr―04 |
Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection |
Yin-Xiao Du, Xiao-Ping Chen |
|
